Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has shared an update.
Giant Biogene Holding Co., Ltd held its Annual General Meeting on June 13, 2025, where all proposed resolutions were approved by shareholders. Key outcomes include the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share repurchases and issuances. Additionally, the company announced the distribution of a final and special dividend for the year ended December 31, 2024, reflecting strong shareholder support and financial stability.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd is a company incorporated in the Cayman Islands, operating within the biotechnology industry. It focuses on developing and providing innovative biotechnological solutions and products.
Average Trading Volume: 9,738,363
Technical Sentiment Signal: Buy
Current Market Cap: HK$63.45B
For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.